May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?

COVID-19 pandemic is a major challenge for global and national healthcare providers. Number of new cases is continuously increasing with an emerging trend showing worse prognosis in males in comparison to females. Based on this observation, our proposed hypothesis is that 5-alpha-reductase inhibitor...

Descripción completa

Detalles Bibliográficos
Autores principales: Adamowicz, Jan, Juszczak, Kajetan, Drewa, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175887/
https://www.ncbi.nlm.nih.gov/pubmed/32344304
http://dx.doi.org/10.1016/j.mehy.2020.109751
_version_ 1783524919315791872
author Adamowicz, Jan
Juszczak, Kajetan
Drewa, Tomasz
author_facet Adamowicz, Jan
Juszczak, Kajetan
Drewa, Tomasz
author_sort Adamowicz, Jan
collection PubMed
description COVID-19 pandemic is a major challenge for global and national healthcare providers. Number of new cases is continuously increasing with an emerging trend showing worse prognosis in males in comparison to females. Based on this observation, our proposed hypothesis is that 5-alpha-reductase inhibitors, that are commonly used for BPH treatment, may be one of the factors contributing to poorer prognosis in males.
format Online
Article
Text
id pubmed-7175887
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71758872020-04-22 May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications? Adamowicz, Jan Juszczak, Kajetan Drewa, Tomasz Med Hypotheses Article COVID-19 pandemic is a major challenge for global and national healthcare providers. Number of new cases is continuously increasing with an emerging trend showing worse prognosis in males in comparison to females. Based on this observation, our proposed hypothesis is that 5-alpha-reductase inhibitors, that are commonly used for BPH treatment, may be one of the factors contributing to poorer prognosis in males. Published by Elsevier Ltd. 2020-07 2020-04-22 /pmc/articles/PMC7175887/ /pubmed/32344304 http://dx.doi.org/10.1016/j.mehy.2020.109751 Text en © 2020 Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Adamowicz, Jan
Juszczak, Kajetan
Drewa, Tomasz
May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
title May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
title_full May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
title_fullStr May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
title_full_unstemmed May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
title_short May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
title_sort may patients receiving 5-alpha-reductase inhibitors be in higher risk of covid-19 complications?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175887/
https://www.ncbi.nlm.nih.gov/pubmed/32344304
http://dx.doi.org/10.1016/j.mehy.2020.109751
work_keys_str_mv AT adamowiczjan maypatientsreceiving5alphareductaseinhibitorsbeinhigherriskofcovid19complications
AT juszczakkajetan maypatientsreceiving5alphareductaseinhibitorsbeinhigherriskofcovid19complications
AT drewatomasz maypatientsreceiving5alphareductaseinhibitorsbeinhigherriskofcovid19complications

Ejemplares similares